Shares of Mirum Pharmaceuticals (MIRM) were up 12.1% this week, driven by investor enthusiasm after the company announced encouraging preliminary sales numbers for the fourth quarter and full year 2024, along with an encouraging outlook and growth strategy for 2025.Mirum’s commercial portfolio comprises of lead product, Livmarli (maralixibat), which is approved for treating cholestatic pruritus in patients with Alagille syndrome worldwide. The drug is also approved for treating certain patients with progres ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, ...

Mirum Pharmaceuticals: Transforming Lives in Rare Disease J a n u a r y 2 0 2 5 Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to managem include all statements other than statements of historical fact contained in this presentation, including information concerning our business strategy, objectives and oppor opportunities for LIVMARLI, CHOLBAM, chenodiol, and Mirum's clinica ...

The Fortune Teller is a team of two analysts with over 30 years of market experience between them. One of the principles is a formerly licensed investment advisor with a background in asset management. They also hold BAs in Accounting & Economics and Computer Sciences, as well as MBAs, which they use to inform their stock selections They lead the investing group They lead the investing group Wheel of Fortune where they share actionable trading ideas across all asset-classes, sectors and industries. The goal ...

Mirum has 3 approved products – LIVMARLI, cholbam and chenodal. LIVMARLI, or maralixibat, is an inhibitor of ileal bile acid transporter, andMirum Pharmaceuticals (NASDAQ: MIRM ) is a liver and rare disease franchise I used to own and cover earlier. I covered it last over a year ago.About the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any t ...

A month has gone by since the last earnings report for Mirum Pharmaceuticals, Inc. (MIRM) . Shares have lost about 0.7% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Mirum Pharmaceuticals due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Mirum's Q3 Earnings & Re ...

Shares of Mirum Pharmaceuticals, Inc. (MIRM) have rallied 90.9% in the past six months compared with the industry’s increase of just 1.1%.The company’s lead product is Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) inhibitor approved for the treatment of cholestatic pruritus in patients with Alagille syndrome worldwide.In March 2024, the FDA approved Livmarli for the treatment of cholestatic pruritus in patients aged five years and older with progressive familial intrahe ...

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Andrew McKibben - Vice President, Investor Relations Chris Peetz - Chief Executive Officer Peter Radovich - President & Chief Operating Officer Joanne Quan - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI. Jessica Fye - JP Morgan Dae Gon Ha - Stifel Brian Skorney - Baird David Lebowitz - Citi Thomas Yip - ...

Mirum Pharmaceuticals, Inc. (MIRM) incurred a loss of 30 cents per share in third-quarter 2024, much narrower than the Zacks Consensus Estimate of a loss of 45 cents. The company had reported a loss of 57 cents per share in the year-ago quarter.Revenues in the third quarter totaled $90.3 million, up 89% year over year. The figure also beat the Zacks Consensus Estimate of $82 million. The top line comprised Livmarli (maralixibat) sales, newly acquired Cholbam and Chenodal sales, and minimal license and other ...

Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.57 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this company would post a loss of $0.48 per share when it actually produced a loss of $0.52, delivering a surprise of -8.33%.Over the last four quarters, the company ...